LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Xencor, Inc.
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Eli Lilly and Company
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC